The Motley Fool
25 Oct 2026, 10:45 UTC · 1h ago
Where Will Neurocrine Biosciences Be in 5 Years?
Impact · against what's priced in
The reported Q2 performance for Neurocrine is a confirmation of the current valuation rather than a catalyst, as the price already expects steady Ingrezza growth and strong margins. While the 2031 revenue target of $6 billion is ambitious, the market continues to discount the pipeline and new product successes required to reach it.
- NBIX+0.00
Already priced in
- The price assumes
Ingrezza's current $2.83bn revenue base and its transition to a slow-growth, cash-generating phase
The raised full-year Ingrezza forecast of $2.825 billion to $2.875 billion aligns almost exactly with the revenue base the market has already priced in.
What NBIX's price assumes · Aug 26
